ReviewCurrent neurology and neuroscience reports2016
Neuropsychiatric Issues in Parkinson's Disease.
Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease.The Cochrane database of systematic reviews · 2025Pooled it
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.Movement disorders : official journal of the Movement Disorder Society · 2017Trial
- Neuroimaging transcriptomic analyses of Parkinson's disease highlight molecular, cellular, and neurobiological mechanisms.NPJ Parkinson's disease · 2025Article
- Depression in Patients With Parkinson's Disease: A Hospital-Based Cross-Sectional Study.Cureus · 2023Article
- Identification and Experimental Validation of Parkinson's Disease with Major Depressive Disorder Common Genes.Molecular neurobiology · 2023Article
- Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Social isolation, loneliness and mental health sequelae of the Covid-19 pandemic in Parkinson's disease.International review of neurobiology · 2022Article
- Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
- Age-Dependent Neuropsychiatric Symptoms in the NF-κB/c-Rel Knockout Mouse Model of Parkinson's Disease.Frontiers in behavioral neuroscience · 2022Article
- Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.Parkinson's disease · 2021Article
- Crocin Reverses Depression-Like Behavior in Parkinson Disease Mice via VTA-mPFC Pathway.Molecular neurobiology · 2020Article
- Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinson's Disease.Brain sciences · 2020Article
- Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson's Disease, and Multiple Sclerosis: Diagnosis and Treatment.Focus (American Psychiatric Publishing) · 2020Article
- Exercise and Parkinson's Disease.Advances in experimental medicine and biology · 2020Review
- Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease.Brain pathology (Zurich, Switzerland) · 2019Article
- Drug testing complementary metal-oxide-semiconductor chip reveals drug modulation of transmitter release for potential therapeutic applications.Journal of neurochemistry · 2019Article
- Comorbid Depression and Psychosis in Parkinson's Disease: A Report of 62,783 Hospitalizations in the United States.Cureus · 2019Article
- Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer's Disease Model.Cell reports · 2019Article
- Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.World journal of psychiatry · 2019Article
- Neuropsychiatric Symptoms and Cognitive Impairment in Chinese Patients with Parkinson's Disease in Han and Hui Ethnicity.Current medical science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive and neuropsychiatric symptoms are common in Parkinson's Disease and may surpass motor symptoms as the major factors impacting patient quality of life. The symptoms may be broadly separated into those associated with the disease process and those that represent adverse effects of treatment. Symptoms attributed to the disease arise from pathologic changes within multiple brain regions and are not restricted to dysfunction in the dopaminergic system. Mood symptoms such as depression, anxiety, and apathy are common and may precede the development of motor symptoms by years, while other neuropsychiatric symptoms such as cognitive impairment, dementia, and psychosis are more common in later stages of the disease. Neuropsychiatric symptoms attributed to treatment include impulse control disorders, pathologic use of dopaminergic medications, and psychosis. This manuscript will review the current understanding of neuropsychiatric symptoms in Parkinson's Disease.
Indexed as
Identifiers
27048443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.